(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.78%.
Atara Biotherapeutics's earnings in 2026 is -$9,467,000.On average, 6 Wall Street analysts forecast ATRA's earnings for 2026 to be -$10,890,595, with the lowest ATRA earnings forecast at -$10,860,861, and the highest ATRA earnings forecast at -$10,785,176. On average, 6 Wall Street analysts forecast ATRA's earnings for 2027 to be $8,225,386, with the lowest ATRA earnings forecast at $6,887,375, and the highest ATRA earnings forecast at $9,555,287.
In 2028, ATRA is forecast to generate -$2,757,113 in earnings, with the lowest earnings forecast at -$4,150,085 and the highest earnings forecast at -$1,229,888.